N/A
Completed N=6
TMS for Veterans Attending a 2-week Intensive Outpatient Program for PTSD
Source: ClinicalTrials.gov NCT06271733 ↗Enrolled (actual)
6
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcomePrimary: PTSD Checklist for DSM-5 (PCL-5) — 30.8 Scores on a Scale
Summary
The goal of this study is to determine whether complementing regular intensive PTSD treatment with intermittent theta burst stimulation (iTBS) applied to the right dorsolateral prefrontal cortex (DLPFC) can improve treatment response for individuals attending a 2-week intensive outpatient program (IOP) for PTSD.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY PTSD Checklist for DSM-5 (PCL-5) |
30.8 | — |
| SECONDARY Patient Health Questionnaire-9 (PHQ-9) |
10.4 | — |
Eligibility Criteria
Inclusion Criteria
- Veterans or service members between the ages of 18 and 65 who are attending the 2- week Intensive Outpatient Program at the Road Home Program and have not had significant PTSD symptom change based on the PCL-5 during the first week of treatment.
- Participants with an HDRS-21 score ≤ 26 at screening visit
Exclusion Criteria
- Individuals with implants and non-removable metals which prevent them from safely receiving TMS, including:
- Aneurysm clips or coils
- Stents in the head, neck, or brain
- Deep brain stimulators
- Metallic implants in the head, neck, or brain (braces and dental implants do not interfere and are safe for TMS)
- Shrapnel or bullet fragments in or near the head
- Facial tattoos with metallic or magnetic-sensitive ink
- Other metal devices or ferromagnetic objects implanted in or near the head
- Pacemakers, intra-cardiac lines, or implanted medical pumps
- Individuals with a history of seizures or epilepsy (except those therapeutically induced by ECT)
- Individuals diagnosed with major, chronic mental health illnesses such as Psychotic Disorders, Bipolar Disorders, and Obsessive Compulsive Disorder
- Individuals with a history of substance abuse within the past six months
- Individuals with significant neurological disorders such as Parkinson's disease, Huntington's chorea, and Multiple sclerosis
- Individuals with unstable physical disease, such as unstable cardiac diseases
- Individuals currently on Benzodiazepine at a dose higher than 3mg or Lorazepam or equivalent.
- Women who are breastfeeding or pregnant
- Individuals with previous TMS treatment
Data sourced from ClinicalTrials.gov (NCT06271733). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.